Granules India Ltd has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Jeedimetla facility in December 2015.
The company said that the USFDA has acknowledged receipt of its responses sent on January 7 and March 28, 2016 on the observations issued by the USFDA for the Jeedimetla facility in December last year.
"The USFDA closed the matter and issued Establishment Inspection Report (EIR) for the Jeedimetla facility situated in the state of Telangana, India,'' the company said in a release issued here on Monday.
Jeedimetla plant manufactures APIs of anti-diabetic drug metformin, expectorant drug guaifenesin and anti-pain methocarbamol.
Granules scrip gained 4.74 per cent on the Bombay Stock Exchange on Monday and is trading at 134.75.